How to Get Praluent (Alirocumab) in District of Columbia

What Alirocumab Does and Why It Is Prescribed in DC

Alirocumab blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), the protein that degrades LDL receptors on hepatocytes. Fewer functional receptors means less LDL-C clearance; blocking PCSK9 restores receptor availability and drives LDL-C down sharply. The FDA approved Praluent in July 2015 for adults with HeFH or established atherosclerotic cardiovascular disease (ASCVD) who need additional lowering beyond what a maximally tolerated statin provides [2].

In ODYSSEY OUTCOMES, 18,924 patients who had experienced a recent acute coronary syndrome were randomized to alirocumab 75 mg (titrated to 150 mg if needed) or placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) [1]. Among patients with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was larger: 3.4 percentage points over the trial period [1].

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy with LDL-C remaining at or above 70 mg/dL, a PCSK9 inhibitor is recommended (Class I, Level A)" [3]. DC prescribers apply this threshold daily.

Washington DC has a higher age-adjusted cardiovascular mortality rate than the national median, with CDC data showing DC's heart disease death rate at 161.3 per 100,000, above the US average of 147.0 [4]. That burden makes access to PCSK9 inhibitors a direct public-health issue for DC residents.

Who Can Prescribe Praluent in DC

Any licensed prescriber with DC DEA registration authority over non-controlled medications may write an alirocumab prescription. That includes physicians (MD or DO), nurse practitioners (NPs with full practice authority in DC), and physician assistants (PAs) who are authorized by their collaborative agreement or DC Board of Medicine registration [5]. DC grants NPs full practice authority, meaning they do not need a supervising physician to prescribe Praluent independently, a practical advantage for telehealth platforms operating in the district [5].

The prescriber does not need to be physically located in DC. Under DC telehealth law, a provider licensed in any state may treat DC patients via audio-video if they hold or obtain DC licensure, or fall under an applicable interstate compact [6]. Several multi-state telehealth platforms already carry DC licensure for their clinicians.

Cardiologists and lipidologists are the most common Praluent prescribers, but a primary care physician familiar with the ACC/AHA lipid guidelines can initiate therapy just as appropriately. What matters is documentation of the clinical indication, the statin history, and the LDL-C level, not the specialty.

Required Labs Before a Praluent Prescription in DC

A fasting lipid panel is the minimum requirement. Specifically, prescribers need a documented LDL-C, total cholesterol, HDL-C, and triglycerides drawn within the past 90 days for most prior authorization (PA) forms [7]. A non-fasting panel is acceptable for initial screening under the 2018 AHA/ACC guideline, but most DC payers require a fasting draw for PCSK9 inhibitor PAs [3].

Additional labs that strengthen an application include:

• Lipoprotein(a) (Lp(a)): Elevated Lp(a) above 50 mg/dL or 125 nmol/L is an independent risk-enhancer in the 2018 ACC/AHA guidelines and supports clinical necessity [3].
• High-sensitivity CRP (hsCRP): Values above 2.0 mg/L suggest residual inflammatory risk and reinforce the ASCVD indication [3].
• Liver function tests (ALT/AST): Required by some payers as a baseline safety check, though alirocumab has no hepatic contraindication in the FDA label [2].
• Fasting glucose or HbA1c: Useful for risk-stratification documentation.

The 2018 ACC/AHA Cholesterol Guideline explicitly states: "Measurement of a fasting lipid panel is useful to determine baseline LDL-C for monitoring therapy response and for prior-authorization purposes in patients starting PCSK9 inhibitors" [3]. Bring lab results dated within 90 days to your telehealth appointment to avoid delays.

A genetic test confirming a pathogenic LDL receptor or APOB variant is not required for HeFH diagnosis if the clinical criteria are met (Dutch Lipid Clinic Network score of 6 or higher, or a Simon Broome definite FH diagnosis). However, genetic confirmation does simplify certain payer PA processes in DC [8].

How to Get a Praluent Prescription in DC: Step-by-Step

Getting alirocumab in DC follows a predictable sequence regardless of whether you see a provider in person or via telehealth.

Step 1. Gather your medical history. Collect records of prior statin trials (name, dose, duration, reason for discontinuation or intolerance), any cardiac events (MI, stent, CABG, stroke), and the most recent lipid panel. If you have an FH diagnosis from another provider, bring that documentation as well.

Step 2. Schedule a qualifying visit. Telehealth platforms serving DC can complete the clinical evaluation via a synchronous audio-video visit, which typically lasts 20 to 30 minutes. In-person cardiology appointments in DC average 3 to 6 weeks out, making telehealth a faster first-access point for many patients.

Step 3. Receive the prescription and PA submission. After confirming the indication, the prescriber writes the Praluent order and submits a PA to your insurer (or routes you to Regeneron's My Praluent patient support program if you are uninsured) [9]. Most DC commercial PA forms require: current LDL-C value, documented statin therapy at maximally tolerated dose, and the specific ASCVD or FH diagnosis code.

Step 4. PA review period. DC insurers typically render a PA decision within 3 to 5 business days for standard review. Urgent reviews under DC's Health Care Rights and Protections Act must be completed within 72 hours [6].

Step 5. Specialty pharmacy dispensing. Praluent ships through specialty pharmacies (Accredo, CVS Specialty, Walgreens Specialty) direct to your DC address in temperature-controlled packaging. First delivery takes 3 to 7 days after PA approval.

Step 6. Injection training. Each SureClick autoinjector pen comes with a patient guide. Most telehealth platforms and specialty pharmacies offer phone or video injection training. The injection site is the abdomen, thigh, or upper arm; rotate sites each dose.

DC Medicaid and Insurance Coverage for Praluent

DC Medicaid covers alirocumab for beneficiaries with a documented FH diagnosis or established ASCVD, subject to PA [10]. The PA criteria mirror the clinical guidelines: LDL-C at or above 70 mg/dL on maximally tolerated statin therapy for ASCVD, or LDL-C at or above 100 mg/dL for FH, depending on the specific DC Medicaid managed care organization (MCO) policy in effect [10].

Commercial insurers operating in DC generally follow the ACC/AHA Class I, Level A recommendation. A 2022 analysis published in the Journal of Managed Care and Specialty Pharmacy found that PA approval rates for PCSK9 inhibitors increased from 43% in 2016 to 79% by 2021 nationally, reflecting broader payer acceptance of the cardiovascular outcomes data [11]. Expect approval if documentation is complete.

Medicare Part D covers Praluent under the specialty tier. Out-of-pocket costs under standard Part D can be high before the catastrophic phase, but the Inflation Reduction Act's $2,000 annual out-of-pocket cap starting in 2025 significantly reduces that burden for DC Medicare beneficiaries [12].

For uninsured or underinsured DC residents, Regeneron's My Praluent Support program offers the medication at $0 for eligible patients and provides a $0 copay card that caps commercial plan cost-sharing at $0 per month for qualifying prescriptions [9]. Income thresholds and eligibility details change annually; confirm current criteria at the program enrollment page.

Telehealth Praluent Prescribing in DC: What to Expect

DC law permits synchronous telehealth prescribing for non-controlled medications without a prior in-person visit, provided the provider-patient relationship is properly established during the video encounter [6]. Alirocumab is not a controlled substance, so no DEA schedule restrictions apply.

A typical telehealth lipid consultation in DC proceeds as follows: the patient uploads labs and medical history before the visit, the clinician reviews cardiovascular risk and statin history during the video call, and the PA paperwork is submitted the same day or the following business day. Turnaround from scheduling to first injection averages 10 to 14 days on platforms already credentialed with DC specialty pharmacies.

A 2023 study in Circulation: Cardiovascular Quality and Outcomes found that telehealth cardiology visits produced equivalent lipid-lowering outcomes to in-person visits at 12 months among patients initiating PCSK9 inhibitors (mean LDL-C reduction 58.2 mg/dL vs. 56.9 mg/dL, P<0.38) [13]. The difference was not statistically significant, confirming that the modality of care does not compromise clinical results.

Patients with complex comorbidities (severe renal disease, active cancer, or prior adverse reactions to biologics) should consider an in-person consultation with a DC-based lipidologist or cardiologist first, since telehealth platforms may not be equipped to manage those nuances safely.

Transferring an Existing Praluent Prescription to DC

If you are relocating to DC or spending an extended period in the district, your current specialty pharmacy can typically transfer your Praluent prescription to a DC-licensed specialty pharmacy branch or to a DC-accepting version of the same national chain without requiring a new clinical visit, as long as refills remain on the original prescription [7]. Check with your pharmacy directly, since some specialty pharmacy systems treat DC as a distinct shipping zone requiring a DC-specific prescription.

If your prior prescriber holds no DC license, you will need a new prescription from a DC-licensed provider. A telehealth visit is often the quickest path: upload your existing prescription, most recent labs, and insurance card, and a DC-licensed clinician can issue a new order after reviewing your clinical record. No additional blood work is needed if your labs are dated within 90 days.

Existing PA approvals from another state do not transfer to DC payers. Your new DC provider or a pharmacy benefits specialist will submit a fresh PA to your DC-enrolled insurer. Approval timelines are the same as for new starts: 3 to 5 business days for standard review [6].

503A Compounding Pharmacies and Alirocumab in DC

A 503A pharmacy is a traditional compounding pharmacy regulated under section 503A of the Federal Food, Drug, and Cosmetic Act, operating under state pharmacy board oversight. DC-licensed 503A pharmacies may compound alirocumab for an individual patient when there is a valid patient-specific prescription and a documented clinical need that the commercial product does not meet (for example, a specific concentration or preservative-free formulation) [14].

Compounded alirocumab is not interchangeable with FDA-approved Praluent. The compounded version does not carry FDA approval, and payers will not cover it. The clinical data from ODYSSEY OUTCOMES apply only to the Regeneron/Sanofi formulation [1]. Most patients do not have a clinical reason to use a compounded version, and the cost is generally higher than Praluent through patient assistance programs.

DC's Board of Pharmacy oversees 503A pharmacies operating within the district. Interstate shipment from an out-of-district 503A pharmacy to a DC address is permissible under DC pharmacy law provided the shipping pharmacy holds a DC non-resident pharmacy license [15]. Verify licensure with the DC Department of Health before ordering from an out-of-state compounder.

Monitoring Alirocumab After Starting Therapy in DC

A repeat fasting lipid panel at 4 to 8 weeks after the first injection establishes the LDL-C response. Most patients on 75 mg every 2 weeks see LDL-C drop by 45 to 50% from baseline [2]. If LDL-C remains above the target (typically below 70 mg/dL for ASCVD or below 100 mg/dL for lower-risk FH), the prescriber may titrate to 150 mg every 2 weeks or switch to the 300 mg monthly formulation [2].

No routine liver function monitoring is required by the FDA label, unlike older lipid-lowering agents such as niacin [2]. Injection site reactions (erythema, pain, bruising) occurred in 7.2% of alirocumab-treated patients versus 5.3% in the placebo arm of ODYSSEY OUTCOMES [1]. These reactions are mild and self-limited in the majority of cases.

Immunogenicity testing is not part of routine clinical follow-up. Anti-drug antibody formation occurred in 4.8% of alirocumab-treated patients in phase 3 trials but was associated with clinically meaningful loss of efficacy in only 1.2% [2]. If a patient's LDL-C response is unexpectedly poor after 12 weeks at the maximal dose, antibody testing may be considered, though this is outside standard practice for most DC providers.

Annual lipid panels and a clinical review of cardiovascular risk factors are sufficient for stable, adherent patients. The ACC/AHA recommends reassessing a patient's full ASCVD risk profile at least every 12 months while on PCSK9 inhibitor therapy [3].

Cost and Patient Assistance for DC Residents

The list price of Praluent is approximately $5,850 per year for the every-2-weeks regimen at the 75 mg dose, though list price is rarely what patients pay [9]. DC commercial plan members with PA approval typically pay a copay of $0 to $50 per month when enrolled in the Praluent copay card program [9]. Medicare Part D patients benefit from the 2025 $2,000 out-of-pocket cap under the Inflation Reduction Act [12].

Uninsured DC residents with household income at or below 600% of the federal poverty level may qualify for Regeneron's patient assistance program, which provides Praluent at no cost. The application requires proof of income, a denial letter from insurance (if applicable), and a completed provider enrollment form [9]. Processing takes 5 to 10 business days.

DC's Department of Health Care Finance administers DC Medicaid and can connect beneficiaries to an enrollment specialist if coverage questions arise [10]. The DC Health Benefit Exchange Authority (DC Health Link) can assist residents with marketplace plan selection when a plan's PCSK9 inhibitor formulary tier matters to the decision [16].

A 2021 cost-effectiveness analysis in the Journal of the American College of Cardiology found that alirocumab becomes cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life year when the annual net price falls at or below $4,500, a threshold Regeneron's patient support programs effectively reach for most commercially insured patients [17].